Comparison of the Xpert breast cancer stratifier mRNA assay with central ER, PR, HER2, and Ki67 immunohistochemistry (IHC) for rapid biomarker analysis in developing countries

被引：0
|
作者：
Brock, J. E.
Milner, D. A.
Ho, K.
Natalie, W.
Victor, C.
Annaliza, R.
Teresa, B.
Kathryn, G-F
Edwin, L. W.
Jodi, W.
Wendy, W.
Michael, B.
机构：
[1] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA
[2] Cepheid, Sunnyvale, CA USA
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.SABCS16-P2-05-07
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2-05-07
引用
收藏
页数：2
相关论文
共 50 条
  • [41] A retrospective study of immunohistochemical detection of Ki67 and correlation with ER, PR, and HER2-neu status in invasive breast cancer
    Prakash, Deepa Meda
    Shivakumar, Swarna
    Bapsy, P. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [42] Comparison of ESR1, PGR, HER2 and KI67 expression by central IHC and MammaTyper® RT-qPCR kit in the FinHer trial
    Wirtz, Ralph M.
    Kellokumpu-Lehtinen, Pirkko-Liisa
    Isola, Jorma
    Kataja, Vesa
    Bono, Petri
    Turpeenniemi-Hujanen, Taina
    Jyrkkio, Sirkuu
    Sitho, Harri
    Eidt, Sebastian
    Sahin, Ugur
    Joensuu, Heikki
    CANCER RESEARCH, 2015, 75
  • [43] Concordance/discordance rates of HER2, ER, PR, and Ki67 in matched pair samples of primary (PBC) and metastatic breast cancer (MBC) tissues when comparing IHC with MammaTyper® RT-PCR kit
    Wallwiener, Markus
    Hartkopf, Andreas
    Deutsch, Thomas
    Sotiris, Lakis
    Taran, Florin-Andrei
    Trumpp, Andreas
    Wirtz, Ralph
    Schneeweiss, Andreas
    CANCER RESEARCH, 2015, 75
  • [44] Central testing of ER, PR, HER2, and Ki67, routinely analyzed at 27 pathology departments in Sweden - Potential consequences for the choice of adjuvant therapy
    Ekholm, Maria
    Grabau, Dorthe
    Bendahl, Per-Ola
    Elmberger, Goran
    Olsson, Hans
    Russo, Leila
    Viale, Guiseppe
    Ferno, Marten
    CANCER RESEARCH, 2015, 75
  • [45] Correlation of miRNA expression profiling in surgical pathology materials, with Ki-67, HER2, ER and PR in breast cancer patients
    Sakurai, Minako
    Masuda, Mariko
    Miki, Yasuhiro
    Hirakawa, Hisashi
    Suzuki, Takashi
    Sasano, Hironobu
    INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2015, 30 (02): : E190 - E199
  • [46] Comparison of central laboratory assessments of ER, PR, HER2, and Ki67 by IHC/FISH and the corresponding mRNAs (ESR1, PGR, ERBB2, and MKi67) by RT-qPCR on an automated, broadly deployed diagnostic platform
    Natalie C. Wu
    Wendy Wong
    Kenneth E. Ho
    Victor C. Chu
    Annaliza Rizo
    Simon Davenport
    Devon Kelly
    Rosemary Makar
    Jacek Jassem
    Renata Duchnowska
    Wojciech Biernat
    Barbara Radecka
    Tomoyuki Fujita
    Jonathan L. Klein
    Mark Stonecypher
    Shoichiro Ohta
    Hartmut Juhl
    Jodi M. Weidler
    Michael Bates
    Michael F. Press
    Breast Cancer Research and Treatment, 2018, 172 : 327 - 338
  • [47] Comparison of central laboratory assessments of ER, PR, HER2, and Ki67 by IHC/FISH and the corresponding mRNAs (ESR1, PGR, ERBB2, and MKi67) by RT-qPCR on an automated, broadly deployed diagnostic platform
    Wu, Natalie C.
    Wong, Wendy
    Ho, Kenneth E.
    Chu, Victor C.
    Rizo, Annaliza
    Davenport, Simon
    Kelly, Devon
    Makar, Rosemary
    Jassem, Jacek
    Duchnowska, Renata
    Biernat, Wojciech
    Radecka, Barbara
    Fujita, Tomoyuki
    Klein, Jonathan L.
    Stonecypher, Mark
    Ohta, Shoichiro
    Juhl, Hartmut
    Weidler, Jodi M.
    Bates, Michael
    Press, Michael F.
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 172 (02) : 327 - 338
  • [48] Study of ER, PR, HER2/neu, p53, and Ki67 expression in primary breast carcinomas and synchronous metastatic axillary lymph nodes
    Khande, Tejal Abasaheb
    Joshi, Avinash R.
    Khandeparkar, Siddhi Gaurish Sinai
    Kulkarni, Maithili M.
    Gogate, Bageshri P.
    Kakade, Aniket R.
    Sahu, Piyush D.
    Khillare, Chaitnya D.
    INDIAN JOURNAL OF CANCER, 2020, 57 (02) : 190 - 197
  • [49] ER, PR, HER2, and Ki67 index and responsiveness to adjuvant tamoxifen in postmenopausal high-risk breast cancer patients enrolled in the DBCG 77C trial
    Knoop, Ann S.
    Laenkholm, Anne-Vibeke
    Jensen, Maj-Britt
    Nielsen, Kirsten V.
    Andersen, Jorn
    Nielsen, Dorte
    Ejlertsen, Bent
    APMIS, 2014, 122 : 12 - 13
  • [50] ER, PR, HER2, and Ki67 index and responsiveness to adjuvant tamoxifen in postmenopausal high-risk breast cancer patients enrolled in the DBCG 77C trial
    Knoop, A. S.
    Laenkholm, A-V
    Jensen, M-B
    Nielsen, K. V.
    Andersen, J.
    Nielsen, D.
    Ejlertsen, B.
    CANCER RESEARCH, 2013, 73
12345